drugset / Trial / NCT00783289
A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of escalating multiple subcutaneous (SC) doses of MEDI-563 in adult subjects with asthma.
Timeline
- Start
- 2008-11-14
- Primary completion
- 2009-11-17
- Completion
- 2009-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benralizumab | Monoclonal antibody | 25 mg | Subcutaneous |
| Subject | Benralizumab | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | Benralizumab | Monoclonal antibody | 200 mg | Subcutaneous |